Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)

NCT01814137 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01814137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01814137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2013
Completion date
March 31, 2014
Enrollment
40 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2